The 10 Advisements

We have the utmost respect for the courage, dedication, and resilience it takes to be an entrepreneur in our industry – especially when you’re out raising your next round of financing. That’s why we’ve decided to share our “10 Advisements” for crafting a compelling fundraising pitch.

We owe it to you – because the best among you have taught us.

What follows is a reflection on what to do (and what not to do), distilled from more than 5,000 pitch presentations we’ve seen over 18 years as a life science investor at Sunstone.

1) Prepare meticulously

Your pitch is one of many – often we evaluate 10–20 opportunities in a single week. You usually get one shot. And if you miss, it can be a while before we circle back.

2) Be self-explanatory

Your deck is often the first touchpoint in the VC process – the meeting is the second or third step. You might never get the chance to clarify your story. Make the deck stand on its own.

3) No more than 30 slides

Link your innovation clearly to the value it creates. Present your team, plan, and budget concisely, and use appendices to provide additional depth. Be efficient – we have a lot to digest.

4) Make it accessible

Your audience may include everyone from medical students to seasoned MDs. They all need to understand your innovation. If your message isn’t clear to a wide range of expertise, it may not land.

5) Let your innovation take center stage

What excites us most is the innovation itself as well as the data that demonstrates and benchmarks its value. Disease focus, team, and budget may amplify that excitement – but rarely replace it.

6) Share data generously

We understand the dilemma of sharing data without an NDA. But often, it’s a single compelling figure – a graph, table, or heatmap – that tips the scales and earns you a follow-up. There may not be a second chance.

7) Pass the Google test

Claims of being the “first,” “best,” or “only” are surprisingly easy to disprove – and often are. Make sure your assertions hold up under a quick Google or ChatGPT search. Whether the search result is right or wrong is irrelevant – it’s the perception that matters.

8) Be personal

Never let an advisor or banker stand between you and the investor. We’re considering investing in you. If you’re not personally engaged, we won’t be either.

9) Manage your fundraising narrative

No one wants to be the last investor you approach. Investors talk. Make sure they all hear the same story – ideally, a good one.

10) Keep it fresh

Your pitch has a shelf life. Like milk on the table, it can go sour. Keep your materials updated with timely data and relevant progress.

And if none of this is news to you – chances are we learned it from you.

What do you think? Feel free to share your thoughts! …and have a great summer!

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Treetop Meeting

We usually do not share updates from internal meetings - but this was too fantastic not to share. A full day meeting in the midst of branches of +100 year old oaks and beech trees overlooking Isefjorden in “the treetop huts” at Ryegaard & Trudsholm Godser. Spiced...

Hans T. Scambye joins Sunstone as Venture Partner

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini...

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

5 latest articles

Is biotech venture capital investing more to return less?

At Sunstone we continue to track risk-adjusted return multiples (adjusted for contingent payments) versus the total capital invested in private therapeutic companies prior to M&A exits. When looking at the median trends over the past 15 years, the inflection...

An update on M&A returns for biotech venture capital

Back in in 2019 Sunstone started sharing studies of European venture capital funded successes – i.e. M&A transactions. In 2021 we started adding US M&A’s to the data and later the same year we evaluated to which extent an IPO impacted the observations made....

Biotech ecosystem contributors!

Biotech ecosystem contributors! In our previous post, we discussed the importance of local investors and how, in a Danish context, they contribute to identifying and scaling local and regional therapeutic innovation. However, not all investors are born equal - and an...

Do local investors make a difference?

Do local investors make a difference? E-mail outreach, online meetings and digital data rooms have become a given when trying to finance a therapeutic innovation! So, do local or regional anchor investors matter when developing a bioinnovation ecosystem? If the local...

Seed & Series A in Denmark

Financing a Danish Biotech company has apparently never been more challenging. Based on feedback from partnering meetings in 2025 it seems that raising Series A financing has become an unprecedented challenge. However, when looking at the available data on the...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...